Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05DBY
|
||||
| Former ID |
DIB002648
|
||||
| Drug Name |
Imagabalin
|
||||
| Synonyms |
Imagabalin hydrochloride; PD-0332334; PD-332334; PF-00195889
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Generalized anxiety disorder [ICD9: 300, 300.02, 311; ICD10:F32, F40-F42, F41.1] | Phase 3 | [531511] | ||
| Company |
Pfizer Inc
|
||||
| Formula |
C9H19NO2
|
||||
| Canonical SMILES |
C(=O)(C[C@H](C[C@@H](CCC)C)N)O
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Voltage-dependent calcium channel subunit alpha-2/delta-1 | Target Info | Agonist | [528162], [531511] | |
| PANTHER Pathway | Muscarinic acetylcholine receptor 2 and 4 signaling pathway | ||||
| References | |||||
| Ref 528162 | Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76. Epub 2006 Apr 26. | ||||
| Ref 531511 | Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.